Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;1(1):1.
doi: 10.1186/s41181-016-0004-6. Epub 2016 Mar 21.

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals

J Koziorowski  1 , M Behe  2 , C Decristoforo  3 , J Ballinger  4 , P Elsinga  5 , V Ferrari  6 , P Kolenc Peitl  7 , S Todde  8 , T L Mindt  9
Affiliations

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals

J Koziorowski et al. EJNMMI Radiopharm Chem. 2017.

Erratum in

Abstract

This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceuticals (RP) that are not approved (i.e., not having a marketing authorization or a monograph in the European Pharmacopoeia), excluding endogenous and ubiquitous substances in humans. This paper discusses the requirements for clinical trials with radiopharmaceuticals for clinical research applications, not necessarily intended to aim at a marketing authorization. If marketing authorization is intended, scientific advice of the competent authorities is mandatory and cannot be replaced by this position paper. The position paper reflects the view of the Radiopharmacy Committee of the EANM and can be used as a basis for discussions with the responsible authorities.

Keywords: Position paper; Pre-clinical toxicology studies; Radiopharmaceuticals.

PubMed Disclaimer

References

    1. Guidance for industry, Developing medical imaging drugs and biological products, Part 1: conducting safety assessments, US Food and Drug Administration, http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071600.pdf.
    1. Guidance for Industry, Investigators and Reviewers, Exploratory IND studies, US Food and Drug Administration, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati....
    1. Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins, EMEA/CHMP/BMWP/14327/2006 Rev. 1, European Medicines Agency, http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/....
    1. Guideline on the limits for genotoxic impurities, CPMP/SWP/5199/02, European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....
    1. ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, EMA/CHMP/ICH/83812/2013, European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....

LinkOut - more resources